A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast|Metastatic|Triple Negative|Cancer|Disseminated Tumor Cell
Interventions: DRUG: Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg or 200 mg plus Capecitabine|COMBINATION_PRODUCT: Sarilumab 150mg plus Capecitabine
Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)